-
Paediatric PK precautions
Monday, November 2, 2020Penetrating keratoplasty is extremely challenging in a paediatric patient population, but favourable outcomes may still be obtained with careful case selection, rigorous surgical technique and meticulous postoperative care
-
Amblyopia treatment evidence
Monday, November 2, 2020Spectacles, patching and atropine have strong evidence as effective treatments for amblyopia, whereas many other treatments must be regarded with a degree of scepticism until they have been studied in rigorous randomised controlled trials
-
New approaches to amblyopia
Monday, November 2, 2020There are many new treatments under investigation for the treatment of amblyopia that may provide useful alternatives to patients who are not amenable or unresponsive to traditional patching
-
New developments in thyroid eye disease
Monday, November 2, 2020Treating a patient with an immobile eye due to thyroid disease requires a multidisciplinary approach that takes into account the entire spectrum of the disease and its impact on the eye
-
PK alternatives
Monday, November 2, 2020Surgeons should remain open to the possibility of trying alternative techniques to penetrating keratoplasty for select cases of congenital corneal opacities in paediatric patients
-
Paediatric cataract surgery
Friday, October 30, 2020Cataract surgery in the younger population is not without risk. Soosan Jacob, MS, FRCS, DNB reports
-
Predicting myopia progression
Thursday, October 1, 2020New data highlight fast progressors best identified using multiple factors
-
Low-dose Avastin for ROP
Thursday, October 1, 2020Smaller dosages of bevacizumab as effective in ROP treatment
-
Binocular video game approach to amblyopia
Monday, September 28, 2020Contrast rebalancing treatments that force both eyes of amblyopic children to work together may provide better outcomes than patching in terms of visual acuity of the affected eye while also enhancing stereoacuity.
-
New monoclonal antibody for thyroid eye disease
Monday, September 28, 2020The introduction and FDA approval of the monoclonal antibody teprotumumab (Tepezza, Horizon Therapeutics) heralds a new era in the treatment of thyroid eye disease
